Evidence map›Paper›PMID 31772037›Full record

ArticleCancer research2020

Eradicating Metastatic Cancer and the Eco-Evolutionary Dynamics of Anthropocene Extinctions.

Robert A Gatenby, Yael Artzy-Randrup, Tamir Epstein, Damon R Reed, Joel S Brown

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Onco-Breastomics: An Eco-Evo-Devo Holistic Approach.International journal of molecular sciences · 2024
    Review
  17. Article
  18. Article
  19. Treatment of evolving cancers will require dynamic decision support.Annals of oncology : official journal of the European Society for Medical Oncology · 2023
    Review
  20. Evolutionary Dynamics and Intermittent Therapy for Metastatic Cancers.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Robert A GatenbyCancer Biology and Evolution Program, Tampa, Florida. Robert.Gatenby@Moffitt.org.ORCID 0000-0002-1621-1510
Yael Artzy-RandrupDepartment of Theoretical and Computational Ecology, IBED, University of Amsterdam, Amsterdam, the Netherlands.ORCID 0000-0003-3958-7892
Tamir EpsteinCancer Biology and Evolution Program, Tampa, Florida.
Damon R ReedDepartment of Interdisciplinary Cancer Management, Moffitt Cancer Center, Tampa, Florida.ORCID 0000-0002-8238-2465
Joel S BrownCancer Biology and Evolution Program, Tampa, Florida.
Moffitt Cancer Center · USRetina Associates of Florida · USDelta Institute for Theoretical Physics · NL

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5M
The Physi(ologi)cal Microenvironment and its Role in Tumor Invasion and MetastaseU54CA143970 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI GATENBY, ROBERT A · 2009 to 2014
$9.3M
Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and ResistanceU01CA232382 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI ANDERSON, ALEXANDER ROBERTSON ALLAN, ANTONIA, SCOTT J. · 2018 to 2022
$3.3M
Imaging Habitats in SarcomaR01CA187532 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI GILLIES, ROBERT J., MARTINEZ, GARY · 2015 to 2019
$2.7M
Application of Evolutionary Principles to Maintain Cancer Control (PQ21)R01CA170595 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI GATENBY, ROBERT A · 2012 to 2015
$2.1M
NCI NIH HHS P30 CA076292NCI NIH HHS R01 CA170595NCI NIH HHS R01 CA187532NCI NIH HHS U01 CA232382NCI NIH HHS U54 CA143970
6 · The paper itself

Abstract

Curative therapy for metastatic cancers is equivalent to causing extinction of a large, heterogeneous, and geographically dispersed population. Although eradication of dinosaurs is a dramatic example of extinction dynamics, similar application of massive eco-evolutionary force in cancer treatment is typically limited by host toxicity. Here, we investigate the evolutionary dynamics of Anthropocene species extinctions as an alternative model for curative cancer therapy. Human activities can produce extinctions of large, diverse, and geographically distributed populations. The extinction of a species typically follows a pattern in which initial demographic and ecological insults reduce the size and heterogeneity of the population. The surviving individuals, with decreased genetic diversity and often fragmented ecology, are then vulnerable to small stochastic perturbations that further reduce the population until extinction is inevitable. We hypothesize large, diverse, and disseminated cancer populations can be eradicated using similar evolutionary dynamics. Initial therapy is applied to reduce population size and diversity and followed by new treatments to exploit the eco-evolutionary vulnerability of small and/or declining populations. Mathematical models and computer simulations demonstrate initial reductive treatment followed immediately by demographic and ecological perturbations, similar to the empirically derived treatment of pediatric acute lymphocytic leukemia, can consistently achieve curative outcomes in nonpediatric cancers. SIGNIFICANCE: Anthropocene extinctions suggest a strategy for eradicating metastatic cancers in which initial therapy, by reducing the size and diversity of the population, renders it vulnerable to extinction by rapidly applied additional perturbations.

Indexed as

Biological EvolutionComputer SimulationEcosystemExtinction, BiologicalModels, TheoreticalHumansNeoplasm MetastasisNeoplasmsPopulation Dynamics

Identifiers

PMID31772037
PMCPMC7771333
OpenAlexW2990286653

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.